John Byrd, Scientific Advisory Board

Dr. John Byrd is an internationally recognized physician-scientist and biotech advisor with over 25 years of experience driving translational research in hematologic malignancies. A pioneer in the clinical development of breakthrough therapies—including rituximab and ibrutinib—Dr. Byrd has played instrumental roles in advancing more than a dozen novel agents from bench to bedside.

Currently, Dr. Byrd serves as the incoming Director of UPMC Hillman Cancer Center and Associate Vice Chancellor for Cancer Affairs at the University of Pittsburgh, where he will oversee all aspects of cancer-related research, education, and clinical care across one of the nation’s largest academic oncology networks. Previously, he chaired the Department of Internal Medicine at the University of Cincinnati and held numerous leadership positions at The Ohio State University Comprehensive Cancer Center.

At DNA Nanobots, Dr. Byrd brings over a decade of collaboration with the company’s founding scientists to his role on the Scientific Advisory Board. He advises on preclinical strategy, translational development, and therapeutic pipeline design—guiding the application of programmable DNA nanoparticles in oncology and immunotherapy.

With more than 700 publications, 23 patents, and advisory experience spanning academia, biopharma, and nonprofit leadership, Dr. Byrd is a driving force in the future of targeted medicine.